PURPOSE: Primary tumor classification of gastric or esophageal cancer has changed significantly with recent alterations of the tumor-node-metastasis (TNM) staging system. Considering these alterations, human epidermal growth factor receptor 2 (HER2) positivity rates were determined and compared in gastric and esophageal adenocarcinoma. Additionally, HER2 positivity in relation to other clinicopathological characteristics was evaluated. METHODS: A total of 321 patients with histologically confirmed invasive gastric or esophageal adenocarcinoma were examined for HER2 by immunohistochemy (IHC) and chromogenic in situ hybridization (CISH). IHC 3+ or IHC 2+/CISH-positive tumors were considered HER2 positive. Clinicopathological characteristics were retrospectively retrieved from the patient records. RESULTS: HER2 positivity was found in 50 of 321 patients (15.6 %). In univariate and multivariate logistic models, HER2 positivity rates were significantly higher in esophageal primary tumors (esophageal 25.0 % vs. gastric 7.4 %) and in intestinal histological tumor type (intestinal 22.6 % vs. diffuse/mixed 5.7 %). No significant differences in HER2 positivity were found between males and females, age below and above 65 years, biopsies and surgical specimens or advanced and early-stage disease. Using the 7th TNM edition, many tumors (30.5 % of all included tumors and 64.5 % of all esophageal primary tumors) previously classified as gastric cancer are now classified as esophageal cancer. CONCLUSIONS: HER2 positivity occurs in 15.6 % of invasive gastroesophageal adenocarcinoma in Western patients, of which the majority is esophageal primary tumors and of the intestinal tumor type. With the introduction of the 7th TNM edition, a large number of tumors previously classified as gastric are now classified as esophageal tumors instead, with relatively high HER2 positivity rates in these esophageal primary tumors.
PURPOSE:Primary tumor classification of gastric or esophageal cancer has changed significantly with recent alterations of the tumor-node-metastasis (TNM) staging system. Considering these alterations, humanepidermal growth factor receptor 2 (HER2) positivity rates were determined and compared in gastric and esophageal adenocarcinoma. Additionally, HER2 positivity in relation to other clinicopathological characteristics was evaluated. METHODS: A total of 321 patients with histologically confirmed invasive gastric or esophageal adenocarcinoma were examined for HER2 by immunohistochemy (IHC) and chromogenic in situ hybridization (CISH). IHC 3+ or IHC 2+/CISH-positive tumors were considered HER2 positive. Clinicopathological characteristics were retrospectively retrieved from the patient records. RESULTS:HER2 positivity was found in 50 of 321 patients (15.6 %). In univariate and multivariate logistic models, HER2 positivity rates were significantly higher in esophageal primary tumors (esophageal 25.0 % vs. gastric 7.4 %) and in intestinal histological tumor type (intestinal 22.6 % vs. diffuse/mixed 5.7 %). No significant differences in HER2 positivity were found between males and females, age below and above 65 years, biopsies and surgical specimens or advanced and early-stage disease. Using the 7th TNM edition, many tumors (30.5 % of all included tumors and 64.5 % of all esophageal primary tumors) previously classified as gastric cancer are now classified as esophageal cancer. CONCLUSIONS:HER2 positivity occurs in 15.6 % of invasive gastroesophageal adenocarcinoma in Western patients, of which the majority is esophageal primary tumors and of the intestinal tumor type. With the introduction of the 7th TNM edition, a large number of tumors previously classified as gastric are now classified as esophageal tumors instead, with relatively high HER2 positivity rates in these esophageal primary tumors.
Authors: Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart Journal: Lancet Date: 2007-01-06 Impact factor: 79.321
Authors: Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: B E Phillips; R R Tubbs; T W Rice; L A Rybicki; T Plesec; C P Rodriguez; G M Videtic; J P Saxton; D I Ives; D J Adelstein Journal: Dis Esophagus Date: 2012-06-07 Impact factor: 3.429
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Harry H Yoon; Qian Shi; William R Sukov; Mark A Lewis; Christopher A Sattler; Anne E Wiktor; Tsung-Teh Wu; Robert B Diasio; Robert B Jenkins; Frank A Sinicrope Journal: J Clin Oncol Date: 2012-09-17 Impact factor: 44.544
Authors: Koen Talsma; Pieter van Hagen; Brechtje A Grotenhuis; Ewout W Steyerberg; Hugo W Tilanus; Jan J B van Lanschot; Bas P L Wijnhoven Journal: Ann Surg Oncol Date: 2012-03-07 Impact factor: 5.344
Authors: Didier Meulendijks; Laurens V Beerepoot; Henk Boot; Jan Willem B de Groot; Maartje Los; James E Boers; Steven A L W Vanhoutvin; Marco B Polee; Aart Beeker; Johanna E A Portielje; Robert S de Jong; Swan H Goey; Maria Kuiper; Karolina Sikorska; Jos H Beijnen; Margot E Tesselaar; Jan H M Schellens; Annemieke Cats Journal: Invest New Drugs Date: 2015-12-08 Impact factor: 3.850
Authors: Mustafa Gürbüz; Erman Akkuş; Abdullah Sakin; Semiha Urvay; Atike Gökçen Demiray; Süleyman Şahin; Teoman Şakalar; Cihan Erol; Mehmet Ali Nahit Şendur; Ahmet Bilgehan Şahin; Erdem Çubukçu; Deniz Can Güven; Saadettin Kılıçkap; Yakup Ergün; Doğan Uncu; Nazım Serdar Turhal; Necdet Üskent; Havva Yeşil Çınkır; Atakan Demir; Ramazan Acar; Nuri Karadurmuş; Sema Türker; Mustafa Altınbaş; Mert Karaoğlan; Filiz Çay Şenler Journal: J Gastrointest Cancer Date: 2021-02-04
Authors: Eva A Ebbing; Jan Paul Medema; Helene Damhofer; Sybren L Meijer; Kausilia K Krishnadath; Mark I van Berge Henegouwen; Maarten F Bijlsma; Hanneke W M van Laarhoven Journal: Oncotarget Date: 2016-03-01
Authors: Ahmed Abdel Hadi; Ali El Hindawi; Amal Hareedy; Heba Khalil; Ranya Al Ashiry; Shady Elia; Ahmed Sadek; Mona Magdy; Rafatt Atta; Amgad Anas; Hisham Bakr; Olfat Hammam Journal: Open Access Maced J Med Sci Date: 2016-09-11